Leptin
- Generic Name
- Leptin
- Drug Type
- Small Molecule
- CAS Number
- 169494-85-3
- Unique Ingredient Identifier
- Q09SXY6BFI
- Background
Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. These people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of insulin. Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite signals from circulating leptin. The high sustained concentrations of leptin from the enlarged fat stores result in the cells that respond to leptin becoming desensitized.
- Indication
Investigated for use/treatment in lipodystrophy and obesity.
A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide
- Conditions
- Obesity
- Interventions
- Drug: Placebo (Normal Saline)
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 10
- Registration Number
- NCT00691158
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Therapeutic Approaches to HAART-Induced Lipodystrophy
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT00461552
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
- Conditions
- HIV Lipodystrophy
- Interventions
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT00362440
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Leptin in Human Energy and Neuroendocrine Homeostasis
- Conditions
- ObesityWeight Loss
- Interventions
- Drug: Subcutaneous Placebo
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 22
- Registration Number
- NCT00265980
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
Leptin and Endothelial Function
- Conditions
- Healthy
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2006-06-27
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 15
- Registration Number
- NCT00121433
Low-Dose Leptin and the Formerly-Obese
- First Posted Date
- 2003-11-19
- Last Posted Date
- 2015-06-04
- Target Recruit Count
- 25
- Registration Number
- NCT00073242
- Locations
- 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States
Effects of Leptin Treatment on Weight Loss
- First Posted Date
- 2002-12-23
- Last Posted Date
- 2010-10-19
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 40
- Registration Number
- NCT00050791
- Locations
- 🇺🇸
Rockefeller University Hospital, New York, New York, United States
Leptin to Treat Severe Insulin Resistance - Pilot Study
- Conditions
- Syndrome
- First Posted Date
- 2001-12-07
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 2
- Registration Number
- NCT00027456
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
Leptin to Treat Lipodystrophy
- Conditions
- Lipodystrophy
- First Posted Date
- 2000-06-12
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 20
- Registration Number
- NCT00005905
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.